Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines
Sign Up to like & getrecommendations! Published in 2019 at "JAMA Oncology"
DOI: 10.1001/jamaoncol.2018.6012
Abstract: Importance The 2013/2014 American Society of Clinical Oncology and College of American Pathologists (ASCO-CAP) guidelines for HER2 testing by fluorescence in situ hybridization (FISH) designated an “equivocal” category (average HER2 copies per tumor cell ≥4-6… read more here.
Keywords: her2 equivocal; alternative control; breast; breast cancers ... See more keywords
NCS‐1 expression is higher in basal breast cancers and regulates calcium influx and cytotoxic responses to doxorubicin
Sign Up to like & getrecommendations! Published in 2019 at "Molecular Oncology"
DOI: 10.1002/1878-0261.12589
Abstract: Neuronal calcium sensor‐1 (NCS‐1) is a positive modulator of IP3 receptors and was recently associated with poorer survival in breast cancers. However, the association between NCS‐1 and breast cancer molecular subtypes and the effects of… read more here.
Keywords: basal breast; breast; breast cancer; breast cancers ... See more keywords
CD26 expression is attenuated by TGF‐β and SDF‐1 autocrine signaling on stromal myofibroblasts in human breast cancers
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Medicine"
DOI: 10.1002/cam4.2249
Abstract: Human breast carcinoma‐associated fibroblasts (CAFs) increasingly acquire both transforming growth factor‐β (TGF‐β) and stromal cell‐derived factor‐1 (SDF‐1) signaling in an autocrine fashion during tumor progression. Such signaling mediates activated myofibroblastic and tumor‐promoting properties in these… read more here.
Keywords: breast cancers; human breast; expression; cd26 expression ... See more keywords
Comparison of the tumor immune microenvironment phenotypes in different breast cancers after neoadjuvant therapy
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5207
Abstract: Neoadjuvant therapy (NAT) treats early‐stage breast cancers, especially triple‐negative breast cancers (TNBCs). NAT improves pathological complete response (pCR) rates for different breast cancer patients. Recently, immune checkpoint inhibitors that target programmed death 1 (PD‐1) or… read more here.
Keywords: breast; tnbc patients; breast cancers; tumor ... See more keywords
A non‐canonical tumor suppressive role for the long non‐coding RNA MALAT1 in colon and breast cancers
Sign Up to like & getrecommendations! Published in 2018 at "International Journal of Cancer"
DOI: 10.1002/ijc.31386
Abstract: Long noncoding RNAs (lncRNAs) constitute one of the largest classes of transcripts and have been widely implicated in various diseases such as cancer. Increasing evidence suggests that several lncRNAs are dysregulated and play critical roles… read more here.
Keywords: colon breast; malat1; breast cancers; non canonical ... See more keywords
Analysis of Ultrasound Features for Breast Cancers With Different Risk Categories and Evaluation of a New Predicting Method
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Ultrasound"
DOI: 10.1002/jcu.23919
Abstract: To explore pathology and ultrasound features of breast cancers with different risk categories. To establish and validate a nomogram primarily based on grayscale ultrasound features for non‐invasive preoperative prediction of high‐risk breast cancers and for… read more here.
Keywords: ultrasound features; breast cancers; risk; cancers different ... See more keywords
Mitochondrial DNA analysis efficiently contributes to the identification of metastatic contralateral breast cancers
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Cancer Research and Clinical Oncology"
DOI: 10.1007/s00432-020-03459-5
Abstract: Purpose In daily practice, a contralateral breast cancer (CBC) is usually considered as a new independent tumor despite the indications of several studies showing that the second neoplasia may be a metastatic spread of the… read more here.
Keywords: contralateral breast; breast; breast cancers; mitochondrial dna ... See more keywords
Does microtubule motor-mediated centrosomal dyshomeostasis confer chemoresistance in breast cancer?
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Mammary Gland Biology and Neoplasia"
DOI: 10.1007/s10911-025-09585-5
Abstract: Chemoresistance is a major challenge in effective chemotherapy for breast cancers. Unfortunately, the precise molecular mechanisms that confer resistance remain elusive so far. A remarkable feature in a multitude of breast cancers is the presence… read more here.
Keywords: breast; breast cancers; microtubule motor; chemoresistance breast ... See more keywords
Origin, activation and heterogeneity of fibroblasts associated with pancreas and breast cancers.
Sign Up to like & getrecommendations! Published in 2022 at "Advances in cancer research"
DOI: 10.1016/bs.acr.2022.03.003
Abstract: Pancreas and breast cancers both contain abundant stromal components within the tumor tissues. A prominent cell type within the stroma is cancer-associated fibroblasts (CAFs). CAFs play critical and complex roles establishing the tumor microenvironment to… read more here.
Keywords: pancreas breast; origin activation; breast cancers; tumor ... See more keywords
[Recent therapeutic trends in triple-negative metastatic breast cancers: PARP inhibitors, immunotherapies and antibody-drug conjugates].
Sign Up to like & getrecommendations! Published in 2021 at "Bulletin du cancer"
DOI: 10.1016/j.bulcan.2020.11.007
Abstract: Compared with other breast cancer subtypes, patients with metastatic triple-negative breast cancer (TNBC) are younger and have a worst overall survival with a median of 15 to 18 months. These tumors have long suffered from… read more here.
Keywords: parp inhibitors; breast; breast cancers; antibody drug ... See more keywords
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers.
Sign Up to like & getrecommendations! Published in 2018 at "Cancer cell"
DOI: 10.1016/j.ccell.2018.08.008
Abstract: We integrated the genomic sequencing of 1,918 breast cancers, including 1,501 hormone receptor-positive tumors, with detailed clinical information and treatment outcomes. In 692 tumors previously exposed to hormonal therapy, we identified an increased number of… read more here.
Keywords: breast cancers; genomic landscape; endocrine resistant; landscape endocrine ... See more keywords